Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The licensed technology possesses proprietary technology and intellectual property rights for the development of pharmaceutical drug formulations that are liposomal and/or emulsion-based formulations and that may incorporate Anti-Nuclear Antibodies (ANA).
Lead Product(s): Dactinomycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: NanoSmart Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 31, 2021